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With approaching the patent cliff for many blockbuster
protein therapeutics approximately 500–1000 Biosimilar can-
didates are currently under development worldwide by an
unexpected high number of players ranging from Biotechs,
Generics, CMOs, Big Pharma but also new cooperate groups
entering Pharma Business.
A central question for the development is how the biosim-
ilarity can be achieved during development and can be
demonstrated to regulatory bodies by state of the art analytics.
Though the principle of similarity of protein products is
well established for demonstrating comparability e.g. during
a process change of an authorized protein therapeutic it is
more complex for biosimilars: There is only limited analytical
knowledge on the reference product for the company devel-
oping a new Biosimilar candidate and most of all there is
an clear increasing demand to apply state of the art protein
analytics.
The proteomics community is on the forefront of develop-
ing new, especially mass spectrometry based technologies for
research, including advanced sample preparation, measure-
ment and data analysis technologies. Thus, the community
largely deﬁned the state of the art in this ﬁeld of exper-
tise. When applying these technologies to the ﬁeld of drug
development and especially to the context of biosimilars, it
soon becomes apparent that the technology needs to be fur-
ther developed in order to meet the challenges of this special
market segment.
The presentation will give an overview on the protein
analytical aspects for Biosimilar development and how pro-
teomics technologies were further evolved.
It will show case studies of comparability with a focus on
quantitative mass spectrometry data. One example will be
the detailed ﬁne structure analysis of Etanercept Originator
in comparison to several Biosimilar Development programs
including a quantitative site speciﬁc O-Glycosylation analysis
(Fig. 1).
Fig. 1 – Monitoring of O-glycosite occupancy of Etanercept
by mass spectrometry [3 batches Originator (blue) versus 3
batches Biosimilar candidate (green)].
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